PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.00%
EBIT growth 1.25-1.5x AGEN's 34.54%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
-9.04%
Negative operating income growth while AGEN is at 7.01%. Joel Greenblatt would press for urgent turnaround measures.
48.96%
Net income growth 1.25-1.5x AGEN's 34.31%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
53.59%
EPS growth 1.25-1.5x AGEN's 39.75%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
51.99%
Diluted EPS growth 1.25-1.5x AGEN's 39.75%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
10.21%
Share count expansion well above AGEN's 8.98%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
6.42%
Diluted share count expanding well above AGEN's 8.98%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-59.54%
Negative OCF growth while AGEN is at 21.76%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-60.23%
Negative FCF growth while AGEN is at 21.96%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7534.43%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-15675.30%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-5709.37%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-6744.35%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-20067.21%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-6838.40%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
530.49%
5Y equity/share CAGR above 1.5x AGEN's 29.99%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
431.75%
Positive short-term equity growth while AGEN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Negative asset growth while AGEN invests at 76.27%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-71.36%
We have a declining book value while AGEN shows 84.71%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-100.00%
We’re deleveraging while AGEN stands at 1.02%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
52.82%
R&D growth drastically higher vs. AGEN's 17.37%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
-14.04%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.